摘要
目的评估CIK细胞过继免疫疗法治疗中、晚期妇科肿瘤的临床疗效。方法参照美国斯坦福大学骨髓移植中心建立的CIK细胞培养方法诱导扩增CIK细胞。培养14 d后分次回输给患者,观察治疗前后瘤体变化、肿瘤标志物变化及生活质量。结果32例接受CIK细胞治疗的中、晚期妇科肿瘤患者中,CR+PR+MR 28例,总缓解率为87.5%,随访1年生存率为90.6%,2年生存率为81.3%,3年生存率为75.0%。生存质量卡氏评分提高率为78.1%,体质量提高率为84.4%;肿瘤标志物CA125显著降低(t=3.95,P<0.05);少数患者有发热反应,大多在38℃以下,未经处理自行退热。结论CIK细胞疗法为无法手术、放疗、化疗的中晚期妇科肿瘤患者,提供了一个可以延长生存期,提高生活质量的新方法。
Objective To estimate the clinical effects on the patients with mid-advanced gynecological carcinoma by cytokine-induced killer （CIK） cells . Methods CIK cells were induced by culturing PBMC of healthy people by incubation in vitro with IL-2, γ-IFN, anti-CD3 monoclonal antibody and IL-1 , then were transfused back to tire patients with mid-advanced gynecological carcinoma after two weeks, for observation of the changes of tumor weight, life quality,tumor markers （TM）. Results The effective rate of CIK ceils was 87.5% （28/32）, after a follow-up 3 years, survival period extend, survival rate was 90.6% after 1 year, after 2 years was 81.3% , and after 3 years was 75.0%. The CA125 from patients with mid-advanced gynecological carcinoma after transfused was significantly lower than that before transfused（ t = 3.95, P 〈 0.05 ） , the Karnofsky＇ s grade and body weight after transfhsed CIK cells were significantly superior to that before transfused. Conclusion CIK cells therapy can enhance the effect of the anti-cancer, improve survival quantity and prolong survival period, which probably can provide a potent immune therapeutic strategy, for patients with mid-advanced gynecological carcinoma.
出处
《肿瘤基础与临床》
2009年第5期428-429,共2页
journal of basic and clinical oncology
关键词
中晚期妇科肿瘤
CIK细胞
过继免疫疗法
mid-advanced gynecological carcinoma
CIK cells
adoptive inununotherapy
